Axsome Therapeutics’ (AXSM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $190.00 target price on the stock.

AXSM has been the topic of several other research reports. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a report on Thursday, December 12th. Mizuho lifted their price target on Axsome Therapeutics from $137.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday. Robert W. Baird upped their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. Finally, Truist Financial upped their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $145.80.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $132.20 on Tuesday. The stock has a market capitalization of $6.41 billion, a P/E ratio of -20.25 and a beta of 1.05. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.19. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm’s 50-day moving average is $95.28 and its two-hundred day moving average is $92.07.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the business earned ($1.32) earnings per share. Equities analysts predict that Axsome Therapeutics will post -4.7 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $64,000. KBC Group NV grew its position in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the period. Finally, Moors & Cabot Inc. acquired a new position in shares of Axsome Therapeutics during the third quarter worth $200,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.